Etrasimod is used for the treatment of moderate to severe ulcerative colitis.[2][4]
Mechanism of action
It works by causing
T cells to become trapped in the
lymph nodes, preventing them from entering the bloodstream, from where they would travel to other tissues in the body and mediate inflammation.[7][8][9][10][11][12]
In December 2023, the
Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Velsipity, intended for the treatment of ulcerative colitis.[4] The applicant for this medicinal product is Pfizer Europe MA EEIG.[4] Etrasimod was approved for medical use in the European Union in February 2024.[4]
^
abcdefg"Velsipity EPAR". European Medicines Agency (EMA). 14 December 2023. Retrieved 17 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, et al. (April 2020). "Modulation of sphingosine-1-phosphate in ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 413–420.
doi:
10.1080/14712598.2020.1732919.
PMID32093531.
S2CID211475181.
^World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3).
hdl:10665/330961.